Steve McCune

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

Geoffrey J. Lindeman, Tharu M. Fernando, Rebecca Bowen et al. · Clinical Cancer Research · 2022 · 86 citations · Full text

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

C. Zhou, Meghna Das Thakur, Manoj Srivastava et al. · Annals of Oncology · 2021 · 64 citations

Oncology, Clinical Trials, Pathology +8

Recombinant human hemoglobins designed for gene therapy of sickle cell disease.

Steve McCune, Muredach P. Reilly, Matthew Chomo et al. · Proceedings of the National Academy of Sciences · 1994 · 63 citations · Full text

In Vivo Gene Therapy, Genetics, Immunology +18

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Federico Cappuzzo, Michael McCleod, Maen Hussein et al. · Annals of Oncology · 2018 · 58 citations

Progression-free Survival, Advanced Non-squamous Nsclc, Medicine +8

Vitamin D deficiency in the spontaneously hypertensive heart failure [SHHF] prone rat

Robert Przybylski, Steve McCune, Bruce W. Hollis et al. · Nutrition Metabolism and Cardiovascular Diseases · 2009 · 43 citations · Full text

Hypertension, Heart Failure, Cardiovascular Disease +7